Quimiorresistencia asociada a enzimas de citocromo P450 en cáncer pulmonar. Revisión descriptiva.
Saved in:
| Title: | Quimiorresistencia asociada a enzimas de citocromo P450 en cáncer pulmonar. Revisión descriptiva. |
|---|---|
| Alternate Title: | Chemoresistance associated with cytochrome P450 enzymes in lung cancer. Descriptive review. |
| Authors: | Valencia-Cervantes, Jesús1,2 jesvalcer@gmail.com, Sierra-Vargas, Martha Patricia1,3 |
| Source: | Revista Biomedica. may2025, Vol. 36 Issue 2, p39-49. 11p. |
| Subjects: | CYTOCHROME P-450, LUNG cancer, DRUG metabolism, DRUG resistance in cancer cells, EPIGENETICS, TREATMENT effectiveness, CELLULAR signal transduction, GENETIC polymorphisms |
| Abstract (English): | Chemoresistance is the main reason for the limited efficacy of cancer therapy. It involves several signaling pathways, such as epigenetic factors, drug transporters, DNA damage repair mechanisms, cell death inhibition, epithelial-mesenchymal transition, and drug metabolism. Cytochrome P450 enzymes are catalytic hemoproteins that metabolize endogenous and exogenous compounds, and their expression influences treatment response. In this descriptive review, we examine the association between the expression or presence of cytochrome P450 enzyme polymorphisms and chemoresistance in lung cancer. A search was performed in PubMed and Science Direct databases using the terms "chemotherapy", "lung cancer" and "CYP450". Ex vivo and in vitro studies of human origin, published in the last 5 years, were included. Review, meta-analysis, and animal model studies were excluded. The search results revealed a total of 173 articles (2020-2024), including three cross-sectional studies involving a total of 179 patients (ex vivo) and two studies with in vitro models, in which the expression or presence of cytochrome P450 enzyme polymorphisms associated with treatment response was evaluated. Selected data describe that expression or polymorphisms of some cytochrome P450 enzyme isoforms, including 1A2, 2A6, 3A4, 1B1, 2C8, 2C9, 27C1, 2D6, are involved in chemoresistance in lung cancer. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | La quimiorresistencia es la principal razón de la eficacia limitada de la terapia contra el cáncer e involucra una serie de vías de señalización, como factores epigenéticos, transportadores de fármacos, mecanismos de reparación de daños del ADN, inhibición de la muerte celular, transición epitelio-mesénquima y metabolismo de los fármacos. Las enzimas del citocromo P450 son hemoproteínas catalíticas que metabolizan compuestos endógenos y exógenos, y su expresión influye en la respuesta del tratamiento. En esta revisión descriptiva se examina la asociación entre la expresión o la presencia de polimorfismos de enzimas de citocromo P450 y la quimiorresistencia en cáncer de pulmón. Se realizó una búsqueda en las bases de datos de PubMed y Science Direct utilizando los términos en inglés: "chemotherapy", "lung cancer" y "CYP450". Se incluyeron los estudios ex vivo e in vitro de origen humano, publicados en los últimos 5 años. Fueron excluidos los trabajos de revisión, metaanálisis y de modelos animales. Los resultados de la búsqueda revelaron un total de 173 artículos (2020-2024), incluidos tres estudios transversales que involucraron un total de 179 pacientes (ex vivo) y dos estudios con modelos in vitro, en los que se evaluó la expresión o la presencia de polimorfismos de enzimas de citocromo P450 asociados con la respuesta al tratamiento. La información seleccionada describe que la expresión o los polimorfismos de algunas isoformas de enzimas de citrocromo P450, incluidas 1A2, 2A6, 3A4, 1B1, 2C8, 2C9, 27C1, 2D6, participan en la quimiorresistencia en cáncer pulmonar. [ABSTRACT FROM AUTHOR] |
| Copyright of Revista Biomedica is the property of Centro de Investigaciones Regionales Dr. Hideyo Noguchi; Facultad de Medicina, UADY and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 188178869 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Quimiorresistencia asociada a enzimas de citocromo P450 en cáncer pulmonar. Revisión descriptiva. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Chemoresistance associated with cytochrome P450 enzymes in lung cancer. Descriptive review. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Valencia-Cervantes%2C+Jesús%22">Valencia-Cervantes, Jesús</searchLink><relatesTo>1,2</relatesTo><i> jesvalcer@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Sierra-Vargas%2C+Martha+Patricia%22">Sierra-Vargas, Martha Patricia</searchLink><relatesTo>1,3</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Revista+Biomedica%22">Revista Biomedica</searchLink>. may2025, Vol. 36 Issue 2, p39-49. 11p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22CYTOCHROME+P-450%22">CYTOCHROME P-450</searchLink><br /><searchLink fieldCode="DE" term="%22LUNG+cancer%22">LUNG cancer</searchLink><br /><searchLink fieldCode="DE" term="%22DRUG+metabolism%22">DRUG metabolism</searchLink><br /><searchLink fieldCode="DE" term="%22DRUG+resistance+in+cancer+cells%22">DRUG resistance in cancer cells</searchLink><br /><searchLink fieldCode="DE" term="%22EPIGENETICS%22">EPIGENETICS</searchLink><br /><searchLink fieldCode="DE" term="%22TREATMENT+effectiveness%22">TREATMENT effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22CELLULAR+signal+transduction%22">CELLULAR signal transduction</searchLink><br /><searchLink fieldCode="DE" term="%22GENETIC+polymorphisms%22">GENETIC polymorphisms</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Chemoresistance is the main reason for the limited efficacy of cancer therapy. It involves several signaling pathways, such as epigenetic factors, drug transporters, DNA damage repair mechanisms, cell death inhibition, epithelial-mesenchymal transition, and drug metabolism. Cytochrome P450 enzymes are catalytic hemoproteins that metabolize endogenous and exogenous compounds, and their expression influences treatment response. In this descriptive review, we examine the association between the expression or presence of cytochrome P450 enzyme polymorphisms and chemoresistance in lung cancer. A search was performed in PubMed and Science Direct databases using the terms "chemotherapy", "lung cancer" and "CYP450". Ex vivo and in vitro studies of human origin, published in the last 5 years, were included. Review, meta-analysis, and animal model studies were excluded. The search results revealed a total of 173 articles (2020-2024), including three cross-sectional studies involving a total of 179 patients (ex vivo) and two studies with in vitro models, in which the expression or presence of cytochrome P450 enzyme polymorphisms associated with treatment response was evaluated. Selected data describe that expression or polymorphisms of some cytochrome P450 enzyme isoforms, including 1A2, 2A6, 3A4, 1B1, 2C8, 2C9, 27C1, 2D6, are involved in chemoresistance in lung cancer. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: La quimiorresistencia es la principal razón de la eficacia limitada de la terapia contra el cáncer e involucra una serie de vías de señalización, como factores epigenéticos, transportadores de fármacos, mecanismos de reparación de daños del ADN, inhibición de la muerte celular, transición epitelio-mesénquima y metabolismo de los fármacos. Las enzimas del citocromo P450 son hemoproteínas catalíticas que metabolizan compuestos endógenos y exógenos, y su expresión influye en la respuesta del tratamiento. En esta revisión descriptiva se examina la asociación entre la expresión o la presencia de polimorfismos de enzimas de citocromo P450 y la quimiorresistencia en cáncer de pulmón. Se realizó una búsqueda en las bases de datos de PubMed y Science Direct utilizando los términos en inglés: "chemotherapy", "lung cancer" y "CYP450". Se incluyeron los estudios ex vivo e in vitro de origen humano, publicados en los últimos 5 años. Fueron excluidos los trabajos de revisión, metaanálisis y de modelos animales. Los resultados de la búsqueda revelaron un total de 173 artículos (2020-2024), incluidos tres estudios transversales que involucraron un total de 179 pacientes (ex vivo) y dos estudios con modelos in vitro, en los que se evaluó la expresión o la presencia de polimorfismos de enzimas de citocromo P450 asociados con la respuesta al tratamiento. La información seleccionada describe que la expresión o los polimorfismos de algunas isoformas de enzimas de citrocromo P450, incluidas 1A2, 2A6, 3A4, 1B1, 2C8, 2C9, 27C1, 2D6, participan en la quimiorresistencia en cáncer pulmonar. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Revista Biomedica is the property of Centro de Investigaciones Regionales Dr. Hideyo Noguchi; Facultad de Medicina, UADY and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=188178869 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.32776/revbiomed.v36i2.1238 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 11 StartPage: 39 Subjects: – SubjectFull: CYTOCHROME P-450 Type: general – SubjectFull: LUNG cancer Type: general – SubjectFull: DRUG metabolism Type: general – SubjectFull: DRUG resistance in cancer cells Type: general – SubjectFull: EPIGENETICS Type: general – SubjectFull: TREATMENT effectiveness Type: general – SubjectFull: CELLULAR signal transduction Type: general – SubjectFull: GENETIC polymorphisms Type: general Titles: – TitleFull: Quimiorresistencia asociada a enzimas de citocromo P450 en cáncer pulmonar. Revisión descriptiva. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Valencia-Cervantes, Jesús – PersonEntity: Name: NameFull: Sierra-Vargas, Martha Patricia IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: may2025 Type: published Y: 2025 Identifiers: – Type: issn-print Value: 0188493X Numbering: – Type: volume Value: 36 – Type: issue Value: 2 Titles: – TitleFull: Revista Biomedica Type: main |
| ResultId | 1 |
